{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:44:35Z","timestamp":1788371075055,"version":"build-2803163510"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>All-oral regimens, including bedaquiline, are now standard in shorter treatment regimens (STRs) for multidrug-resistant tuberculosis (MDR-TB). Resistance or intolerance to drugs in STR often necessitates a switch to longer treatment regimens (LTRs). This study aims to identify the factors associated with this transition in MDR-TB patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of medical records from MDR-TB patients treated with STR at Haji Hospital, Surabaya, between January 2022 and January 2023. Data on drug-resistance profiles, determined by drug-susceptibility testing (DST), and line probe assay, as well as adverse effects, were collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among 20 eligible patients, 8 (40.0%) switched from STR to LTR within the first 4 months. Resistance was observed in 62.5% of these patients for pyrazinamide, 25.0% for high-dose isoniazid, and 12.5% for levofloxacin. The overall prevalence of pyrazinamide resistance was 25.0%. A history of prior antitubercular treatment was significantly associated with pyrazinamide resistance (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.015; RR \u2013 16.000; confidence interval 95% 1.274\u2013200.917).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Pyrazinamide resistance is a major factor for switching from STR to LTR in MDR-TB patients, particularly among those with previous TB treatment. Rapid DST for pyrazinamide is essential for the early identification of resistance and timely adjustments to treatment regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijmy.ijmy_164_24","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T15:00:44Z","timestamp":1734620444000},"page":"430-435","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Pyrazinamide Resistance: A Major Cause of Switching Shorter to Longer Bedaquiline-based Regimens in Multidrug-resistant Tuberculosis Patients"],"prefix":"10.4103","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1218-4372","authenticated-orcid":false,"given":"Oki Nugraha","family":"Putra","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Hang Tuah University, Surabaya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur","family":"Indah","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Haji Hospital, Surabaya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Telly","family":"Purnamasari","sequence":"additional","affiliation":[{"name":"BRIN, Cibinong, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Larasanti","sequence":"additional","affiliation":[{"name":"Research Unit, Haji Hospital, Surabaya"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"R1-20241219","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/jpdtsm.jpdtsm_133_23","article-title":"Evaluating diagnostic utility of geneXpert ultra (Mycobacterium tuberculosis\/rifampicin), microscopy and liquid culture to isolate Mycobacterium tuberculosis and nontuberculous mycobacteria among pulmonary tuberculosis suspects","volume":"2","author":"Gota","year":"2023","journal-title":"J Prev Diagn Treat Strat Med"},{"key":"R3-20241219","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/ijmy.ijmy_217_22","article-title":"Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: A systematic review","volume":"12","author":"Putra","year":"2023","journal-title":"Int J Mycobacteriol"},{"key":"R4-20241219","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5588\/ijtld.17.0660","article-title":"Principles for constructing a tuberculosis treatment regimen: The role and definition of core and companion drugs","volume":"22","author":"Van Deun","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"R5-20241219","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1186\/s12879-021-06666-8","article-title":"Efficacy of bedaquiline in the treatment of drug-resistant tuberculosis: A systematic review and meta-analysis","volume":"21","author":"Wang","year":"2021","journal-title":"BMC Infect Dis"},{"key":"R7-20241219","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4103\/bbrj.bbrj_26_18","article-title":"Epidemiology of multi-drug-resistant tuberculosis in Northern India","volume":"2","author":"Kumar","year":"2018","journal-title":"Biomed Biotechnol Res J"},{"key":"R8-20241219","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4103\/jpdtsm.jpdtsm_144_23","article-title":"Tuberculosis prevention, diagnosis, and treatment financial profile during 2006-2021: Part B","volume":"3","author":"Madadi-Goli","year":"2024","journal-title":"J Prev Diagn Treat Strategies Med"},{"key":"R9-20241219","first-page":"1576","article-title":"Factors cause of switching shorter regimen to longer regimen in multidrug-resistant\/rifampicin-resistant tuberculosis treated patients in Dr. Soetomo hospital Surabaya, Indonesia","volume":"15","author":"Soedarsono","year":"2021","journal-title":"Indian J Forensic Med Toxicol"},{"key":"R10-20241219","doi-asserted-by":"crossref","first-page":"e0270003","DOI":"10.1371\/journal.pone.0270003","article-title":"Risk factors for multidrug-resistant tuberculosis: A worldwide systematic review and meta-analysis","volume":"17","author":"Xi","year":"2022","journal-title":"PLoS One"},{"key":"R11-20241219","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4103\/bbrj.bbrj_53_19","article-title":"Second-line drug susceptibilities of multidrug- and rifampicin-resistant Mycobacterium tuberculosis isolates in Delhi","volume":"3","author":"Sidiq","year":"2019","journal-title":"Biomed Biotechnol Res J"},{"key":"R12-20241219","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4103\/ijmy.ijmy_40_23","article-title":"Mycobacterium tuberculosis \u2013 Atpe gene profile of bedaquiline-treated pulmonary tuberculosis patients at the referral hospital Dr. Soetomo, Indonesia","volume":"12","author":"Setyawan","year":"2023","journal-title":"Int J Mycobacteriol"},{"key":"R13-20241219","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4103\/bbrj.bbrj_131_19","article-title":"Effectiveness of the shorter MDR regimen in the management of tuberculosis: Shortfall in the outcome of disease a multidimensional approach and evaluation for a better alternative","volume":"4","author":"Das","year":"2020","journal-title":"Biomed Biotechnol Res J"},{"key":"R14-20241219","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcimb.2023.1134036","article-title":"The cause-effect relation of tuberculosis on incidence of diabetes mellitus","volume":"13","author":"Bisht","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"R15-20241219","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.5588\/ijtld.20.0048","article-title":"Treatment outcomes in patients with drug-resistant TB-HIV co-infection treated with bedaquiline and linezolid","volume":"24","author":"Padayatchi","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"key":"R16-20241219","first-page":"855","article-title":"Comparison of chest X-ray findings between primary and secondary multidrug resistant pulmonary tuberculosis","volume":"5","author":"Septafianty","year":"2021","journal-title":"Bioscientia Medicina J Biomed Transl Res"},{"key":"R17-20241219","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12865-023-00563-2","article-title":"Higher plasma interleukin - 6 levels are associated with lung cavitation in drug-resistant tuberculosis","volume":"24","author":"Maseko","year":"2023","journal-title":"BMC Immunol"},{"key":"R18-20241219","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4081\/monaldi.2021.1675","article-title":"Factors associated with time to sputum culture conversion of rifampicin-resistant tuberculosis patients in Klaipeda, Lithuania in 2016-2019: A cohort study","volume":"91","author":"Diktanas","year":"2021","journal-title":"Monaldi Arch Chest Dis"},{"key":"R19-20241219","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1093\/cid\/ciy611","article-title":"Levofloxacin pharmacokinetics\/pharmacodynamics, dosing, susceptibility breakpoints, and artificial intelligence in the treatment of multidrug-resistant tuberculosis","volume":"67","author":"Deshpande","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R20-20241219","doi-asserted-by":"crossref","first-page":"e00279","DOI":"10.1128\/AAC.00279-19","article-title":"Fluoroquinolones in drug-resistant tuberculosis: Culture conversion and pharmacokinetic\/pharmacodynamic target attainment to guide dose selection","volume":"63","author":"Al-Shaer","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-20241219","doi-asserted-by":"crossref","first-page":"372","DOI":"10.4103\/ijmy.ijmy_143_23","article-title":"A critical review of risk factors influencing the prevalence of extensive drug-resistant tuberculosis in India","volume":"12","author":"Khan","year":"2023","journal-title":"Int J Mycobacteriol"},{"key":"R22-20241219","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.52225\/narra.v3i3.407","article-title":"Profile and risk factors of pre-XDR-TB and XDR-TB patients in a national reference hospital for Sumatra region of Indonesia","volume":"3","author":"Sinulingga","year":"2023","journal-title":"Narra J"},{"key":"R23-20241219","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jgar.2020.11.011","article-title":"Fluroquinolone drug resistance among MDR-TB patients increases the risk of unfavourable interim microbiological treatment outcome: An observational study","volume":"24","author":"Singh","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"R24-20241219","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1186\/s12879-019-4384-6","article-title":"Factors associated with isoniazid resistant tuberculosis among human immunodeficiency virus positive patients in Swaziland: A case-control study","volume":"19","author":"Dlamini","year":"2019","journal-title":"BMC Infect Dis"},{"key":"R26-20241219","doi-asserted-by":"crossref","first-page":"e00021","DOI":"10.1128\/AAC.00021-19","article-title":"Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis","volume":"63","author":"Xu","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R27-20241219","doi-asserted-by":"crossref","first-page":"e20180254","DOI":"10.1590\/1806-3713\/e20180254","article-title":"Serum pyrazinamide concentrations in patients with pulmonary tuberculosis","volume":"45","author":"Lucena","year":"2019","journal-title":"J Bras Pneumol"},{"key":"R28-20241219","doi-asserted-by":"crossref","first-page":"107","DOI":"10.15562\/bmj.v8i1.1304","article-title":"Therapeutic drug monitoring of rifampicin, isoniazid, and pyrazinamide in newly-diagnosed pulmonary tuberculosis outpatients in Denpasar area","volume":"8","author":"Widhiarti","year":"2019","journal-title":"Bali Med J"},{"key":"R29-20241219","doi-asserted-by":"crossref","first-page":"e0004621","DOI":"10.1128\/AAC.00046-21","article-title":"Factors affecting the pharmacokinetics of pyrazinamide and its metabolites in patients coinfected with HIV and implications for individualized dosing","volume":"65","author":"Sundell","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-20241219","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.2147\/IDR.S260161","article-title":"Pyrazinamide resistance and mutation patterns among multidrug-resistant Mycobacterium tuberculosis from Henan province","volume":"13","author":"Shi","year":"2020","journal-title":"Infect Drug Resist"},{"key":"R31-20241219","doi-asserted-by":"crossref","first-page":"100411","DOI":"10.1016\/j.jctube.2023.100411","article-title":"Resistance to pyrazinamide in Mycobacterium tuberculosis complex isolates from previously treated tuberculosis cases in Southwestern Oromia, Ethiopia","volume":"34","author":"Balay","year":"2024","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"R32-20241219","doi-asserted-by":"crossref","first-page":"544","DOI":"10.5588\/ijtld.17.0483","article-title":"Impact of pyrazinamide resistance on multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan","volume":"22","author":"Kuhlin","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"R33-20241219","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12879-020-4758-9","article-title":"Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China","volume":"20","author":"Xia","year":"2020","journal-title":"BMC Infect Dis"},{"key":"R34-20241219","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/IDR.S436161","article-title":"Prevalence, transmission and genetic diversity of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Hunan, China","volume":"17","author":"Liu","year":"2024","journal-title":"Infect Drug Resist"},{"issue":"Suppl 1","key":"R35-20241219","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.ijtb.2023.01.006","article-title":"Drug resistance patterns and treatment outcomes in DR-TB patients at a tertiary care Centre in Mumbai","volume":"71","author":"Mohan","year":"2024","journal-title":"Indian J Tuberc"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_164_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:44:05Z","timestamp":1787067845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_164_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmy.ijmy_164_24","relation":{},"ISSN":["2212-5531","2212-554X"],"issn-type":[{"value":"2212-5531","type":"print"},{"value":"2212-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"2024-08-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}